Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Two drugs widely used to treat certain autoimmune diseases substantially improved clinical status and reduced deaths.
Vaccines designed to produce a strong T cell response may help protect against current and future SARS-CoV-2 variants.
Nearly 200 cases of pediatric hepatitis have now been reported in more than a dozen countries and several states.
New laws make it easier for people to see their loved ones in health care facilities during the pandemic.
Paxlovid and molnupiravir can reduce the risk of severe COVID-19, but they must be started within five days of symptom onset.
Though such cases may not always amount to debilitating long COVID, it is common to take weeks to fully recover.
The United States might see one of the steepest increases in the country’s uninsured rate in years.
CoVac-1 induced T-cell responses in about 90% of immunocompromised people with impaired B-cell function.
NIAID is preparing for the possibility of future variants evading protection against currently available COVID-19 vaccines.
While vaccination typically provides robust protection against severe disease, they’re less effective for immunocompromised people.
Novel therapies, improved technologies and a better understanding of the immune system could yield broad dividends.
Immunocompromised people ages 12 and older are also eligible for an additional shot.
Protecting the immunocompromised is not only a matter of health equity, it’s critical to ending the pandemic.
Researchers showed that B cells evolve after COVID-19 vaccination to help improve protection against SARS-CoV-2 over time.
The CDC’s move triggered mixed feelings from the public and laid bare a split within the health care community.
Transplant recipients, people with advanced HIV and certain people with cancer or autoimmune diseases can get an additional vaccine dose.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.